一种用于克服非小细胞肺癌治疗中抗原异质性的多靶向 CAR-T 细胞平台
A Multi-Targeting Chimeric Antigen Receptor-T Cell Platform to Overcome Antigen Heterogeneity in the Treatment of Non-Small Cell Lung Cancer.
这些发现支持采用多靶点CAR-T 策略来应对NSCLC及可能其他实体瘤中的抗原异质性。
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
英文原题:E3 ligase TRIM28 promotes anti-PD-1 resistance in non-small cell lung cancer by enhancing the recruitment of myeloid-derived suppressor cells.
E3 ligase TRIM28 promotes anti-PD-1 resistance in non-small cell lung cancer by enhancing the recruitment of myeloid-derived suppressor cells.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
本研究确定 TRIM28 通过 RIPK1 介导的 NF-κB 激活促进趋化因子驱动的 MDSCs 募集,从而导致浸润性活化 CD8 + T 细胞受到抑制并产生抗 PD-1 耐药。了解 TRIM28 对 MDSC 募集和功能的调控,为理解 TRIM28 信号与免疫抑制性肿瘤微环境发展之间的关联提供了关键见解。这些见解可能为开发联合疗法以增强 NSCLC 中免疫检查点阻断疗法的有效性提供信息。
几种含三重基序(TRIM)家族蛋白的改变已被认为与肺癌的发病机制有关。TRIM28是TRIM E3连接酶家族的一员,与肿瘤发生、细胞增殖和炎症有关。然而,关于TRIM28在非小细胞肺癌(NSCLC)免疫微环境中的表达及其作用,目前知之甚少。
我们评估了TRIM28在组织微阵列和TCGA队列中的临床意义。我们在同源小鼠肿瘤模型、Kras LSL-G12D/+ ; Tp53 fl/fl (KP)小鼠模型和人源化小鼠中研究了TRIM28的功能。使用流式细胞术和免疫组织化学分析了免疫细胞组成。
我们的研究结果揭示了在NSCLC中,TRIM28表达与抑制性髓源性抑制细胞(MDSCs)的浸润呈正相关。此外,沉默TRIM28通过重塑炎性肿瘤微环境增强了抗PD-1免疫治疗的疗效。在机制上,我们证明TRIM28能够与受体相互作用蛋白激酶1(RIPK1)发生物理相互作用,并促进RIPK1的K63连接泛素化,这对于维持NF-κB通路的激活至关重要。E3连接酶结构域的突变证实了E3连接酶活性在TRIM28介导的NF-κB激活中的关键作用。进一步实验揭示,TRIM28能够通过激活NF-κB信号通路上调CXCL1的表达。CXCL1能够与MDSCs上的CXCR2结合,并促进其向肿瘤微环境迁移。TRIM28敲低增加了免疫健全小鼠对抗PD-1治疗的应答,其特征为CD8+ TTIL(肿瘤浸润淋巴细胞)增加和MDSCs减少。
Alterations in several tripartite motif-containing (TRIM) family proteins have been implicated in the pathogenesis of lung cancer. TRIM28, a member of the TRIM E3 ligase family, has been associated with tumorigenesis, cell proliferation, and inflammation. However, little is known about TRIM28 expression and its role in the immune microenvironment of non-small cell lung cancer (NSCLC).
We assessed the clinical significance of TRIM28 in tissue microarrays and TCGA cohorts. We investigated the function of TRIM28 in syngeneic mouse tumor models, the Kras LSL-G12D/+ ; Tp53 fl/fl (KP) mouse model, and humanized mice. Immune cell composition was analyzed using flow cytometry and immunohistochemistry.
Our findings revealed a positive correlation between TRIM28 expression and the infiltration of suppressive myeloid-derived suppressor cells (MDSCs) in NSCLC. Moreover, silencing TRIM28 enhanced the efficacy of anti-PD-1 immunotherapy by reshaping the inflamed tumor microenvironment. Mechanistically, we demonstrated that TRIM28 could physically interact with receptor-interacting protein kinase 1 (RIPK1) and promote K63-linked ubiquitination of RIPK1, which is crucial for sustaining activation of the NF-κB pathway. Mutagenesis of the E3 ligase domain corroborated the essential role of E3 ligase activity in TRIM28-mediated NF-κB activation. Further experiments revealed that TRIM28 could upregulate the expression of CXCL1 by activating NF-κB signaling. CXCL1 could bind to CXCR2 on MDSCs and promote their migration to the tumor microenvironment. TRIM28 knockdown increased responsiveness to anti-PD-1 therapy in immunocompetent mice, characterized by increased CD8 + T tumor-infiltrating lymphocytes and decreased MDSCs.
The present study identified TRIM28 as a promoter of chemokine-driven recruitment of MDSCs through RIPK1-mediated NF-κB activation, leading to the suppression of infiltrating activated CD8 + T cells and the development of anti-PD-1 resistance. Understanding the regulation of MDSC recruitment and function by TRIM28 provides crucial insights into the association between TRIM28 signaling and the development of an immunosuppressive tumor microenvironment. These insights may inform the development of combination therapies to enhance the effectiveness of immune checkpoint blockade therapy in NSCLC.
在 PubMed 查看 → 出版商原文(DOI) 全文 PDF(PMC)· 可下载 治疗专题与资料阅读指南 资料来源与翻译说明 报告译文或资料问题 →
MEMBER ACCOUNT
登录成功会直接打开下一页。